During Q3 2018 the big money sentiment increased to 1.47. That’s change of 0.33, from 2018Q2’s 1.14. 0 investors sold all, 17 reduced holdings as Psychemedics Corporation ratio increased. 17 rose positions while 8 funds amassed positions. Funds hold 2.92 million shares thus 3.02% more from 2018Q2’s 2.84 million shares.
Seizert Prns Limited Liability Corp holds 0.02% or 30,179 shs. Great West Life Assurance Can has invested 0% in Psychemedics Corporation (NASDAQ:PMD). Janney Montgomery Scott Ltd Co reported 11,550 shs stake. New York-based Blackrock has invested 0% in Psychemedics Corporation (NASDAQ:PMD). Janney Cap Ltd Co owns 0% invested in Psychemedics Corporation (NASDAQ:PMD) for 11,550 shs. Renaissance Limited Company holds 0.01% of its capital in Psychemedics Corporation (NASDAQ:PMD) for 468,066 shs. Bancorporation Of Ny Mellon invested in 40,124 shs. Moors Cabot Inc owns 57,832 shs or 0.13% of their US capital. Bancorporation Of America Corporation De stated it has 0% of its capital in Psychemedics Corporation (NASDAQ:PMD). Lpl Limited Liability Com holds 0% of its capital in Psychemedics Corporation (NASDAQ:PMD) for 22,405 shs. Vanguard Grp holds 0% or 221,531 shs. Fmr Lc owns 297 shs or 0% of their US capital. Moreover, Quantum Capital Mngmt has 0.44% invested in Psychemedics Corporation (NASDAQ:PMD). Blair William And Il owns 0.01% invested in Psychemedics Corporation (NASDAQ:PMD) for 106,733 shs. Kennedy Cap Mngmt invested 0.02% in Psychemedics Corporation (NASDAQ:PMD).

Psychemedics Corporation had 1 sale and 0 buys since September 6, 2018. This’s net activity of $121,611.

Psychemedics Corporation (NASDAQ:PMD) showed a decrease of 6.82% in short interest. In March was issued PMD’s total 8,200 short interest by FINRA. The down change of 6.82% from 8,800 shares was reported. Previous PMD’s position will need 1 days to restore. It has 9,200 average volume. 0.18% is Psychemedics Corporation float short.

The stock decreased 0.61% or $0.12 during the last trading session, reaching $19.44.Psychemedics Corporation has volume of 5,710 shares. Since March 2, 2018 PMD has declined 24.93% and is downtrending. PMD underperformed by 24.93% the S&P 500.

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally.The firm is worth $107.06 million. The companyÂ’s tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time.17.83 is the P/E ratio. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, and opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine.

For more Psychemedics Corporation (NASDAQ:PMD) news published recently go to: Benzinga.com, Globenewswire.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas – Benzinga” published on December 19, 2018, “James Abely Promoted to VP and General Counsel at Psychemedics Corporation – GlobeNewswire” on May 08, 2018, “Eoptolink Heads to OFC With 7nm-Based 400G DR4/FR4 Transceivers – Nasdaq” with a publish date: January 31, 2019, “Psychemedics Corporation (PMD) Ex-Dividend Date Scheduled for November 01, 2018 – Nasdaq” and the last “Ambu A/S: Interim Report for Q1 2018/19 – Nasdaq” with publication date: January 31, 2019.